Helix Biopharma Corp. HBPCF
—
1.71
0.00
0.00%
as of 24 Sep
- Market cap
- —
- P/E
- 0.0×
Follow HBPCF
Growth Flags
show if company had growth for consecutive years
| Older periods | Jul '25 | Oct '25 | Jan '26 | Apr '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(67.19%) | (65.79%) | (54.46%) | (49.65%) | |
| (51.21%) | (49.56%) | (40.34%) | (29.64%) | ||
ROIC |
(21.21%) | (18.32%) | (16.32%) | (16.60%) | |
Return on Tangible Assets |
185.69% | 207.87% | 137.97% | 89.55% | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.05) | (0.04) | (0.04) | (0.03) | |
Free Cash Flow |
(2.73) | (3.00) | (2.69) | (2.37) | |
Capital Expenditures |
0.01 | — | — | — | |
Piotroski F-Score |
2.00 | 2.00 | 2.00 | 3.00 | |
| Other line items | |||||
Cash ROIC |
(23.96%) | (24.58%) | (23.68%) | (18.19%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | — | — | — | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.74 | 0.86 | 0.89 | 0.98 | |
Depreciation/Fixed assets |
2.48 | 4.07 | 7.43 | 4.43 | |
Capex/Depreciation |
1.69 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.05) | (0.04) | (0.04) | (0.03) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | — | — | — | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates